Application
Cetrorelix, a luteinizing hormone releasing hormone receptor (LHRHR) antagonist, was used to study its safety, mechanism of action, metabolism, and efficacy as a therapeutic agent for the treatment of blood cancers such as multiple myeloma (MM). Cetrorelix is used to evaluate its effects on a wide range of physiological processes and malignancies that involve luteinizing hormone releasing hormone receptor signaling pathways involving processes such as steroidogenesis.
Biochem/physiol Actions
Cetrorelix acetate is a luteinizing hormone releasing hormone receptor antagonist. It causes prepubertal reduction in bone modeling, bone density and bone strength comparable to post-menopausal bone loss.
Features and Benefits
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 51111840
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- C5249-25MG